Caudal Dexamethasone - Bupivacaine in Neonates
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: We add Dexamethasone to Bupivacaine as adjuvant to Bupivacaine in neonsates undergoing inguinal hernia repair in Dexamethasone - Bupivacaine group.
- Who it may be relevant to
- Registry conditions: We Are Studying the Effects of Caudal Dexamethasone in Neonates Undergoing Inguinal Hernia Repair. Basic parameters: 1 Day — 28 Days · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Analgesic Efficacy Of Dexamethasone As Adjuvant To Caudal Bupivacaine For Neonates Undergoing Inguinal Hernia Repair: Randomized Controlled Study
Overview
Randomied controlled study Evaluate the effects of caudal Dexamethasone in neonates
Detailed description
Evaluate the additive analgesic effects of caudal Dexamethasone in neonates undergoing inguinal hernia repair.
additive side effects if found
Interventions
- Procedure We add Dexamethasone to Bupivacaine as adjuvant to Bupivacaine in neonsates undergoing inguinal hernia repair in Dexamethasone - Bupivacaine group
We add Dexamethasone to Bupivacaine as adjuvant to Bupivacaine in neonates undergoing inguinal hernia repair
Primary outcome measures
- FLACC pain scale (face,leg , activity,cry, consolability) in the first 24 hours postoperative [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- full term neonate
- ASA I \& ASA II
- Scheduled for inguinal hernia repair
Exclusion criteria
- Patients with allergies to studied drugs
- body weight <3 kilograms
- parents refusal
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07609836 · O6U-ERC-0136